Objectives: To determine whether intracerebroventricular injection of GalR1 agonist M617 would elevate GLUT4 expression in the cardiac muscle of type 2 diabetic rats. 

Methods: The rats tested were divided into four groups: rats from healthy and type 2 diabetic drug groupswere injected with 10 nM/kg/dM617 in5 μl . Cardiac muscle was processed for determination of GLUT4 mRNA expression and GLUT4 protein levels. 

Results : The present findings showed that  the GLUT4 content in the cardiac muscle in both drug groups was higher compared with each control. M617 treatment increased GLUT4 mRNA expression . 

Conclusions: These observations suggest that GalR1 agonist M617 can promote GLUT4 expression and enhance GLUT4 content in the cardiac muscle of type 2 diabetic rats.